J9277 Pembrolizumab and berahyaluronidase alfa-pmph - CanMED: HCPCS

Return Home

Home

SEER Data & Software

Observational Research in Oncology Toolbox

Medication Information

CanMED: HCPCS

Generic Name:

Pembrolizumab and berahyaluronidase alfa-pmph

Brand Name:

KEYTRUDA QLEX

Strength:

1mg

HCPCS:

J9277

SEER*Rx Category:

Immunotherapy

Major Drug Class:

Checkpoint Inhibitor

Minor Drug Class:

PD-1

Oral (Y/N):

No

FDA Approval Year:

2025

FDA Discontinuation Year:

CMS Effective Date:

March 18, 2026

CMS Discontinuation Date:

Status:

In Use